StreetInsider.com News Articles

Form 4 ABEONA THERAPEUTICS INC. For: Jul 21 Filed by: Vazzano Joseph Walter

Wed, 22 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260722/26802139.html

Form 4 ABEONA THERAPEUTICS INC. For: Jul 21 Filed by: Vazzano Joseph Walter

Wed, 22 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260722/26802139.html

Cincinnati Children's becomes seventh treatment site for Abeona's Zevaskyn

Tue, 21 Jul 2026 07:31:58 -0400

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center for ZEVASKYN (prademagene zamikeracel), a gene-modified cellular sheet therapy for wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

RDEB is a rare genetic skin disorder in which patients lack functional type VII collagen, causing the skin to blister and form wounds that can lead to life-threatening complications. ZEVASKYN incorporates a functional copy of the COL7A1 gene into a patient's own skin cells to produce the missing protein in treated wounds.

Cincinnati Children's is described in the press release as one of the largest epidermolysis

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Tue, 21 Jul 2026 07:30:00 -0400

CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN^® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Tue, 21 Jul 2026 07:30:00 -0400

“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Tue, 21 Jul 2026 07:30:00 -0400

CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Tue, 21 Jul 2026 07:30:00 -0400

CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Tue, 21 Jul 2026 07:30:00 -0400

CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Tue, 21 Jul 2026 07:30:00 -0400

CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with

Form 4 ABEONA THERAPEUTICS INC. For: Jul 09 Filed by: Vazzano Joseph Walter